Ocugen, Inc.

NasdaqCM:OCGN Voorraadrapport

Marktkapitalisatie: US$273.3m

Ocugen Beheer

Beheer criteriumcontroles 2/4

Ocugen's CEO is Shankar Musunuri, appointed in Sep 2013, has a tenure of 11.17 years. total yearly compensation is $4.54M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.65% of the company’s shares, worth $1.78M. The average tenure of the management team and the board of directors is 1.8 years and 4.8 years respectively.

Belangrijke informatie

Shankar Musunuri

Algemeen directeur

US$4.5m

Totale compensatie

Percentage CEO-salaris16.7%
Dienstverband CEO11.2yrs
Eigendom CEO0.7%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur4.8yrs

Recente managementupdates

Recent updates

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Sep 14

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Aug 23

Ocugen Q2 2022 Earnings Preview

Aug 04

Ocugen: A First Take

Jul 18

Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant

Jul 05

Analyse CEO-vergoeding

Hoe is Shankar Musunuri's beloning veranderd ten opzichte van Ocugen's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$5mUS$758k

-US$63m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$8mUS$715k

-US$87m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$8mUS$541k

-US$58m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$500k

-US$34m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$572kUS$420k

-US$20m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$431kUS$420k

-US$18m

Compensatie versus markt: Shankar's total compensation ($USD4.54M) is above average for companies of similar size in the US market ($USD1.48M).

Compensatie versus inkomsten: Shankar's compensation has been consistent with company performance over the past year.


CEO

Shankar Musunuri (60 yo)

11.2yrs

Tenure

US$4,535,231

Compensatie

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. since September 2013 and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Pr...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Shankar Musunuri
Co-Founder11.2yrsUS$4.54m0.65%
$ 1.8m
Uday Kompella
Co-founder & Independent Director11.2yrsUS$102.13k0.24%
$ 669.3k
Arun Upadhyay
Chief Scientific Officer and Head of Research & Development2.2yrsUS$1.38m0.038%
$ 103.6k
Ramesh Ramachandran
Chief Accounting Officerless than a yeargeen gegevensgeen gegevens
John Kouch
General Counselno datageen gegevensgeen gegevens
Tiffany Hamilton
AVP & Head of Corporate Communicationsno datageen gegevensgeen gegevens
Kristen Craft
Head of People & Cultureless than a yeargeen gegevensgeen gegevens
Michael Shine
Senior Vice President of Commercial3.4yrsgeen gegevensgeen gegevens
Jyothy Pillai
VP & Head of Regulatory & Quality1.8yrsgeen gegevensgeen gegevens
Huma Qamar
Chief Medical Officerless than a yeargeen gegevens0.00057%
$ 1.6k
Durgaprasad Annavajjula
VP, Head of Program Management & Chief of Staffless than a yeargeen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: OCGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Shankar Musunuri
Co-Founder5.2yrsUS$4.54m0.65%
$ 1.8m
Uday Kompella
Co-founder & Independent Director5.2yrsUS$102.13k0.24%
$ 669.3k
Prabhavathi Fernandes
Lead Independent Director4.6yrsUS$124.63k0%
$ 0
Marna Whittington
Independent Director2.7yrsUS$103.32k0.00035%
$ 956.4
Carl Regillo
Member of Retina Scientific Advisory Board5yrsgeen gegevensgeen gegevens
David Boyer
Member of Retina Scientific Advisory Boardno datageen gegevensgeen gegevens
Bruce Forrest
Vaccine Scientific Advisory Board Member3.9yrsgeen gegevensgeen gegevens
Junge Zhang
Independent Director5.2yrsUS$87.13k0.40%
$ 1.1m
Geeta Lalwani
Member of Retina Scientific Advisory Boardno datageen gegevensgeen gegevens
Kirsten Castillo
Independent Director4.6yrsUS$110.82k0.017%
$ 47.5k
Satishchandran Chandrasekhar
Vaccine Scientific Advisory Board Member3.9yrsgeen gegevensgeen gegevens
Mark Pennesi
Member of Retina Scientific Advisory Board5yrsgeen gegevensgeen gegevens

4.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: OCGN's board of directors are considered experienced (4.8 years average tenure).